Ryder, Hamish,Escardo, Jordi Gras,Calvo, Jesus Llenas,Diaz, Pio Orviz
申请号：
NO20065482
公开号：
NO338621B1
申请日:
2006.11.28
申请国别(地区):
NO
年份:
2016
代理人:
摘要：
Combination (I) comprises a phosphodiesterase inhibitor 4 (PDE4) (A) and an antagonist of M3 muscarinic receptors (B) (3(R)-(2-hydroxy-2, 2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo [2.2.2] octane), in the form of a salt having an anion X (anion of a mono or polyvalent acid). An independent claim is also included for a method of treating a patient suffering from or susceptible to a respiratory disease or condition which responds to M3 antagonism comprising simultaneous, concurrent, separate or sequential administration of (I). ACTIVITY : Antiasthmatic Respiratory-Gen. Antiinflammatory. MECHANISM OF ACTION : Phosphodiesterase-4 inhibitor Muscarinic receptors antagonist Leukotriene-D4 antagonist Neurokinin-1- receptor antagonist Epidermal growth factor receptor kinase inhibitor Beta-2 agonist p38 Kinase inhibitor.En kombinasjon som omfatter (a) et kortikosteroid og (b) en antagonist av M3-muskarinreseptorer som er 3(R)-(2hydroksy-2,2-ditien-2-ylacetoksy)-1-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan, i form av et salt som har et anion X, som er et farmasøytisk akseptabelt anion av en én- eller flerverdig syre.
